

**RECEIVED
CENTRAL FAX CENTER**

DEC 07 2004

PILLSBURY WINTHROP LLP

725 SOUTH FIGUEROA STREET SUITE 2800 LOS ANGELES, CA 90017-5406 213.488.7100 F: 213.639.1033

Total Pages (including cover): 3

FACSIMILE	Date:	Must Be Sent By:	
HOUSTON	To:	Examiner Shin Lin Chen	Fax No: (703) 872-9306
LONDON	Company:	United States Patent and Trademark Office	Phone No: (571)272-0726
LOS ANGELES	Confirm:	Confirmed By:	
NEW YORK	From:	Seth D. Levy	Phone No: (213) 488-7131
NORTHERN VIRGINIA	User No:	14240	C/M No: 081476-0305616
ORANGE COUNTY	Comments:		
SACRAMENTO	Applicants:	Melmed <i>et al.</i>	
SAN DIEGO	Serial No.:	09/978,146	
SAN FRANCISCO	Filing Date:	October 15, 2001	
SILICON VALLEY	For:	<i>PTTG KNOCKOUT RODENT AS A MODEL TO STUDY MECHANISMS FOR VARIOUS PHYSIOLOGICAL PHENOMENA, INCLUDING DIABETES</i>	
SINGAPORE			
STAMFORD			
SYDNEY			
TOKYO			
WASHINGTON DC			

M 7 5 07

Confidentiality Note:
 The documents accompanying this facsimile transmission may contain confidential information which is legally privileged. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of any of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please immediately notify us by telephone and mail the original transmission to us. Thank you.

PLEASE SEE ATTACHED

If you have not properly received this fax, please call (213) 488-7577. Thank you.

Operator: _____ Time Sent: _____ Batch ID: _____

PATENT
81476-305616RECEIVED
CENTRAL FAX CENTERApplicants: Melmed *et al.*

DEC 07 2004

Serial No.: 09/978,146

Filing Date: October 15, 2001

For: *PTTG KNOCKOUT RODENT AS A MODEL TO STUDY MECHANISMS FOR
VARIOUS PHYSIOLOGICAL PHENOMENA, INCLUDING DIABETES*


Dear Examiner Chen:

Thank you for speaking with me about revisions to the claims of this application. In our telephone conversation, you indicated that claims 42-54 and 56-59 were in condition for allowance (claims 1-51 and 55 were previously canceled), but that claims 60-65 may not be allowable under 35 U.S.C. § 101, for a lack of utility.

The Applicants hereby request the cancellation of claims 60-65 via Examiner's Amendment. In addition, also via Examiner's Amendment, please add new claim No. 66, which is listed on the attached page and, per your suggestion, describes a method for screening drug candidates for treating certain disease conditions using the null mutant mouse of the invention.

Please let me know if this new claim is acceptable. If you have any questions or concerns, please do not hesitate to contact me directly. Thank you for your continued assistance in this matter.

Best regards,



Seth D. Levy, Esq.
Reg. No. 44,869

PILLSBURY WINTHROP LLP
725 South Figueroa Street
Suite 2800
Los Angeles, CA 90017-5406

Tel: 213.488.7131
Fax: 213.226.4187

E-mail: SLevy@PillsburyWinthrop.com

PATENT
81476-305616APPLICANTS' PROPOSED NEW CLAIM

66. (New) A method for screening a drug candidate for therapeutic treatment of a disease condition selected from the group consisting of diabetes, hyperglycemia, hypoinsulinaemia, and hypoleptinemia, comprising:

providing a null mutant mouse comprising in its germ cells an artificially induced PTTG null mutation on both PTTG alleles, wherein said mutation results in said mouse exhibiting at least one phenotype selected from the group consisting of hyperglycemia, hypoinsulinaemia, hypoleptinemia, diabetes, chromosomal aneuploidy, premature centromere division, chromosomal damage, aberrant mitotic cellular division, thrombocytopenia, thymic hyperplasia, splenic hypoplasia, testicular hypoplasia, and female subfertility, the prevalence of which is greater than in a mouse lacking said mutation;

administering said drug candidate to said mouse; and

determining potential efficacy of said drug candidate for the treatment of said disease condition based on a response of said mouse to said drug candidate.